publication . Article . 2018

RESPOSTA PATOLÓGICA COMPLETA (YPT0 YPN0) APÓS QUIMIOTERAPIA E RADIOTERAPIA NEOADJUVANTES SEGUIDO DE ESOFAGECTOMIA NO CARCINOMA EPIDERMÓIDE AVANÇADO DO ESÔFAGO: RESULTADOS E SOBREVIDA

Nelson Adami ANDREOLLO; Giovanni de Carvalho BERALDO; Iuri Pedreira Filardi ALVES; Valdir TERCIOTI-JUNIOR; José Antonio Possato FERRER; João de Souza COELHO-NETO; Luiz Roberto LOPES;
Open Access English
  • Published: 06 Dec 2018 Journal: Arquivos Brasileiros de Cirurgia Digestiva : ABCD, volume 31, issue 4 (issn: 0102-6720, eissn: 2317-6326, Copyright policy)
  • Publisher: Colégio Brasileiro de Cirurgia Digestiva
Abstract
ABSTRACT Background: Esophageal squamous cell carcinoma is an aggressive neoplasia that requires a multidisciplinary treatment in which survival and prognosis are still not satisfactory. The complete pathologic response to neoadjuvant chemotherapy and radiotherapy is considered a good prognosis factor, and esophagectomy is indicated. Aim: Survival analysis of cases with pathologic complete response (ypT0 ypN0) to neoadjuvant chemotherapy and/or radiotherapy, submmitted to esophagectomy. Methods: Between 1983-2014, 222 esophagectomies were performed, and 177 were conducted to neoadjuvant treatment. In 34 patients the pathologic response was considered complete. M...
Subjects
free text keywords: Original Article, Esophagectomy, Esophageal carcinoma, Radiotherapy, Chemotherapy, Neoadjuvant therapy, Esofagectomia, Carcinoma do esôfago, Radioterapia, Quimioterapia, Terapêutica neoadjuvante, Radiation therapy, medicine.medical_treatment, medicine, Carcinoma, medicine.disease, Radiology, medicine.medical_specialty, Cell, medicine.anatomical_structure, Esophagus, business.industry, business
Related Organizations
48 references, page 1 of 4

al-Sarraf, M. Cisplatin combinations in the treatment of head and neck cancer. Semin Oncol. 1994; 21 (5 Suppl 12): 28-34

Andreollo, NA, Tercioti, V, Lopes, LR, Coelho-Neto, J de S. Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus. Arq Gastroenterol. 2013; 50 (2): 101-106 [PubMed]

Bain, GH, Petty, RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas combining clinical, imaging, and molecular biomarkers. Oncologist. 2010; 15 (3): 270-284 [OpenAIRE] [PubMed]

Tustumi, F, Kimura, CM, Takeda, FR, Uema, RH, Salum, RA, Ribeiro-Junior, U, Cecconello, I. Prognostic factors and survival analysis in esophageal carcinoma. Arq Bras Cir Dig. 2016; 29 (3): 138-141 [OpenAIRE] [PubMed]

Bollschweiler, E, Hölscher, AH, Schmidt, M, Warnecke-Eberz, U. Neoadjuvant treatment for advanced esophageal cancer response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res. 2015; 27 (3): 221-230 [OpenAIRE] [PubMed]

Chao, YK, Yeh, CJ, Chuang, WY, Fan, KH, Hsieh, MJ, Chu, Y, Cheng, AJ, Liu, HP. Prognostic significance of immunohistochemically detected lymph node micrometastases in pT0N0 esophageal squamous cell carcinoma. J Surg Oncol. 2009; 100 (7): 559-562 [PubMed]

Chao, YK, Liu, HP, Hsieh, MJ, Wu, YC, Liu, YH, Yeh, CH, Chang, HK, Tseng, CK. Lymph node dissection after chemoradiation in esophageal cancer a subgroup analysis of patients with and without pathological response. Ann Surg Oncol. 2012; 19 (11): 3500-3505 [PubMed]

Chiu, CH, Chao, YK, Chang, HK, Tseng, CK, Chan, SC, Liu, YH, Chen, WH. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma does delayed surgery impact outcome?. Ann Surg Oncol. 2013; 20 (13): 4245-4251 [PubMed]

Dittrick, GW, Weber, JM, Shridhar, R, Hoffe, S, Melis, M, Almhanna, K, Barthel, J, McLoughlin, J, Karl, RC, Meredith, KL. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012; 19 (5): 1678-1684 [PubMed]

Donahue, JM, Nichols, FC, Li, Z, Schomas, DA, Allen, MS, Cassivi, SD. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009; 87 (2): 392-398 [OpenAIRE] [PubMed]

Haisley, KR, Hart, KD, Nabavizadeh, N, Bensch, KG, Vaccaro, GM, Thomas, CR, Schipper, PH, Hunter, JG, Dolan, JP. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer. Dis Esophagus. 2017; 30 (7): 1-7

Herskovic, A, Al-Sarraf, M. Combination of 5-Fluorouracil and Radiation in Esophageal Cancer. Semin Radiat Oncol. 1997; 7 (4): 283-290 [PubMed]

Herskovic, A, Russell, W, Liptay, M, Fidler, MJ, Al-Sarraf, M. Esophageal carcinoma advances in treatment results for locally advanced disease review. Ann Oncol. 2012; 23 (5): 1095-1103 [PubMed]

Hsu, PK, Chien, LI, Huang, CS, Hsieh, CC, Wu, YC, Hsu, WH, Chou, TY. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma does neoadjuvant chemoradiation benefit all?. Interact Cardiovasc Thorac Surg. 2013; 17 (3): 460-466 [OpenAIRE] [PubMed]

Hulshof, MC, van Laarhoven, HW. Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. Best Pract Res Clin Gastroenterol. 2016; 30 (4): 551-563 [PubMed]

48 references, page 1 of 4
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2018

RESPOSTA PATOLÓGICA COMPLETA (YPT0 YPN0) APÓS QUIMIOTERAPIA E RADIOTERAPIA NEOADJUVANTES SEGUIDO DE ESOFAGECTOMIA NO CARCINOMA EPIDERMÓIDE AVANÇADO DO ESÔFAGO: RESULTADOS E SOBREVIDA

Nelson Adami ANDREOLLO; Giovanni de Carvalho BERALDO; Iuri Pedreira Filardi ALVES; Valdir TERCIOTI-JUNIOR; José Antonio Possato FERRER; João de Souza COELHO-NETO; Luiz Roberto LOPES;